Cambridge, UK – 22 July, 2026 – Healx, an AI-powered, clinical-stage biotech company dedicated to rare diseases, today announced that the first patient has been dosed in its Phase 1/2 dose-escalation and dose-confirmation clinical trial to evaluate the safety and efficacy of HLX-4310, an investigational oral combination of a class I selective HDAC inhibitor and an mTOR inhibitor, in adolescents and adults with relapsed, refractory sarcoma, with a focus on osteosarcoma.
Osteosarcoma is a rare, aggressive bone cancer that most often affects children, adolescents, and young adults.…
Leadership expansion reinforces ELRIG's commitment to delivering impactful drug discovery initiatives and driving community-wide collaboration
Cambridge, UK, 21 July 2026: ELRIG, a not-for-profit, volunteer-led organisation dedicated to the global drug discovery community, has appointed Drs Hitesh Sanganee and Marcus Schindler to its Scientific Advisory Board (SAB). Their appointments strengthen ELRIG's scientific leadership and reinforce the organisation's commitment to delivering relevant, forward-thinking scientific programmes that reflect the evolving needs of the drug…
We recently hosted our Ask the Experts Live Q&A: From Preclinical to First-in-Human.
In this session, our experts explored the strategic decisions that shape early clinical success, covering key considerations for transitioning from preclinical development into first-in-human studies. Drawing on their extensive experience, they discussed common challenges, practical approaches to reducing development risk, and the critical decisions that can help keep programmes on track.
If you coldn't join us live, the full recording is now available to watch on demand at your convenience: https://…
Pioneer Group, a specialist life science infrastructure and venture building business, and Firoka, a hospitality and real estate group, have secured unanimous resolution to grant planning permission for the transformation of Ozone Leisure Park in Oxford.
The decision marks a major milestone for Ozone Oxford, a new mixed-use campus that will bring together research, workspace, leisure and community facilities on the existing Ozone Leisure Park site.
It follows planning approval granted earlier this year for Pioneer Group's redevelopment of 1–12 Magdalen Street, the former Debenhams…
A Supportive Membership Offer While You Plan Your Next Step: One Nucleus Creates a New Membership Category for
Those Who Find Themselves Between Life Science Jobs
Cambridge UK: 15 July 2026
Being made redundant, or finding yourself between roles for any reason, can be an unsettling time. It can also be an important moment to reconnect with your professional community, explore new opportunities, and invest in your next step.
One Nucleus sits firmly behind those wishing to continue their careers in the Life Sciences industry, whether seeking employment in a similar role or…
Some of the UK's most promising student food innovators gathered at Colworth Science Park this month for the 2026 Ecotrophelia UK final, where seven university teams presented eco-innovative food concepts to a panel of industry judges.
Hosted at Gastronomica, a home for ambitious food-tech businesses advancing the future of food, set within Colworth Science Park, the competition challenged finalists to develop sustainable food products with real commercial potential as part of a long-running European initiative designed to support the next generation of food and drink innovators.…
Strengthens multiomics portfolio offering metabolite-level insight to connect molecular data with biological function across broader life science studies
New workflow built around Thermo Scientific Vanquish UHPLC coupled with Orbitrap Exploris 120 high-resolution accurate-mass mass spectrometry
Cambridge, UK, 13 July 2026: Novogene Europe, a multiomics research services partner, today announced that it has strengthened its position as a multiomics partner with the launch of its Untargeted Metabolomics Service through its Cambridge Omics Centre. This new capability will help researchers…
Amsbio report how its biospecimens were used in a large-scale immuno-oncology study analysing Fibroblast Activation protein (FAP) expression across 23 tumour types, contributing to new insights into biomarker development for cancer immunotherapies.
Scientists at Roche Pharma Research used both immunohistochemistry and RNA sequencing techniques to assess expression patterns. The study highlights the value of top-quality human tumour samples for translational immunology research in complex tumour microenvironment biology,
The authors of the study describe how elevated FAP expression was…
Boyds, a leading global drug development consultancy, is pleased to announce the appointment of Laurence Skillern as Chief Medical Officer.
Laurence joins Boyds with extensive experience in pharmaceutical medicine and clinical development, bringing a strong track record of leadership across the development and delivery of innovative therapies. In his new role, Laurence will be responsible for leading and strengthening Boyds’ medical and clinical strategy, supporting clients across the full spectrum of drug development, and further enhancing the company’s medical and regulatory expertise.…
Myricx Bio to be Acquired by Novartis to Advance Next-Generation ADC Payloads for Oncology with Novel NMTi Platform
• Potential first-in-class N-myristoyltransferase inhibitor (NMTi) ADC payload with a differentiated mechanism of action
• Combines oncology expertise of Novartis with Myricx Bio’s novel ADC assets and platform having broad potential across multiple solid tumour types
• Transaction valued at up to $1.5 billion including $1.1 billion cash upfront
London, UK 6 July 2026 - Myricx Bio, a UK-headquartered biotech company focusing on the discovery and development of a novel class of…